Abstract 1364P
Background
SAF-189s is a next-generation inhibitor of ALK/ROS1 tyrosine kinase, which has been shown to have anti-tumor activity against ALK/ROS1 fusion-positive non-small-cell lung cancer (NSCLC), including CNS activity due to its ability to penetrate the blood-brain barrier. Here we present a circulating tumor DNA (ctDNA) biomarker analysis of patients (pts) with advanced, ALK-rearranged NSCLC treated in phase 2a study.
Methods
Tumor tissue samples were collected from all enrolled pts for ALK-fusion detection by VENTANA ALK (D5F3) IHC assay. Plasma samples were collected at baseline and disease progression. Next-generation sequencing for ctDNA was done using Lung cancer 180-gene panel (Genetron). PFS was evaluated according to ALK alteration status.
Results
By the cut-off date of Dec 13th, 2021 (median PFS follow-up 11 mo), a total of 143 NSCLC ALK-fusion positive pts had been enrolled and treated with SAF-189s (80 mg, n=19; 120 mg, n=47, 160 mg, n=64; 210 mg, n=13), including 100 ALKi-naïve pts and 43 ALKi-refractory pts (received crizonitib and/or next-generation ALKi). ctDNA at baseline was tested in 143 pts with a ALK-fusion positivity rate of 53.8% (77/143). The main fusion partner of ALK was EML4, accounting for 93.6% (73/78). The most common fusion variants were v3 (34.5%, 27/78), v1 (28.2%, 22/78), and v2 (10.3%, 8/78). Pts with v1 variants showed a longer mPFS than v3 variants (16.5 mo vs. 13.8 mo, p=0.188). There was no significant difference in the distribution of ALK fusion variants between ALKi-naïve and ALKi-refractory groups. Of 25 pts who progressed with SAF-189s, two ALK mutations, G1202R and I1179T, were newly identified in 3 pts. I1179T has not been previously reported and is speculated to be a novel ALK-resistant mutation. TP53 co-mutations were detected in 47% pts, but it was not shown to have a significant effect on outcomes. Gene co-occurrence survival analysis showed that mPFS of pts harboring FAT3/FAT4 mutations were significantly shorter than those without FAT3/FAT4 mutations (8.9 mo vs 16.5 mo, p=0.012).
Conclusions
Clinical utility of ctDNA was demonstrated, not only at baseline by identifying fusion types and subgroups of ALK+ NSCLC pts that may benefit more from SAF-189s, but also at progression by tracking ALK-resistant mutations.
Clinical trial identification
NCT04237805.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
Funding
Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19